Cargando…

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

MiR-34a acts as tumor suppressor microRNA (miRNA) in several cancers, including multiple myeloma (MM), by controlling the expression of target proteins involved in cell cycle, differentiation and apoptosis. Here, we have investigated the combination between miR-34a and γ-secretase inhibitor (γSI), S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarone, Mayra Rachele, Misso, Gabriella, Grimaldi, Anna, Zappavigna, Silvia, Russo, Margherita, Amler, Evzen, Di Martino, Maria Teresa, Amodio, Nicola, Tagliaferri, Pierosandro, Tassone, Pierfrancesco, Caraglia, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738363/ https://www.ncbi.nlm.nih.gov/pubmed/29263373 http://dx.doi.org/10.1038/s41598-017-18186-0

Ejemplares similares

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma
por: Misso, Gabriella, et al.
Publicado: (2019)

Mir-34: A New Weapon Against Cancer?
por: Misso, Gabriella, et al.
Publicado: (2014)

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
por: Scognamiglio, Immacolata, et al.
Publicado: (2014)

In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
por: Amodio, Nicola, et al.
Publicado: (2012)

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
por: Raimondi, Lavinia, et al.
Publicado: (2016)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer
por: Abate, Marianna, et al.
Publicado: (2023)

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
por: Amodio, Nicola, et al.
Publicado: (2015)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
por: Amodio, Nicola, et al.
Publicado: (2019)

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2013)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity
por: Raimondi, Lavinia, et al.
Publicado: (2014)

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
por: Tassone, P, et al.
Publicado: (2012)

In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

miR-22 suppresses DNA ligase III addiction in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2018)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer
por: Coradduzza, Donatella, et al.
Publicado: (2022)

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma
por: Juli, Giada, et al.
Publicado: (2019)

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma
por: Cosco, Donato, et al.
Publicado: (2015)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Analysis of miRNA, mRNA, and TF interactions through network-based methods
por: Guzzi, Pietro H, et al.
Publicado: (2015)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2016)

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
por: Amodio, N, et al.
Publicado: (2012)

Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling
por: Russo, Mario, et al.
Publicado: (2020)

A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma
por: Zappavigna, Silvia, et al.
Publicado: (2019)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
por: Tagliaferri, P, et al.
Publicado: (2012)

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2015)

Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
por: Piccolo, Marialuisa, et al.
Publicado: (2019)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pcdt456pdu4r4thvi974iptvqm